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Abstract
Background. This paper reports a series of patients with Mirizzi’s syndrome (MS) who were managed at our institution over
an 11-year (19942005) period. Methods. Retrospective case note study of patients with a definitive or possible diagnosis of
MS stated in radiology reports were identified using the hospital’s radiology computer coding system. Results. 33 patients
were identified with a median age of diagnosis of 70 (3590) years and male to female ratio of 15:18. Liver function tests
were deranged in all patients. Pre-operative radiological diagnosis was achieved in 28 patients: ultrasound scan (n/4),
computer tomography (n/3), magnetic resonance cholangiopancreatography (n/10) and endoscopic retrograde
cholangiopancreatography (n/11). Five patients were diagnosed intra-operatively. Type I MS was reported in 27 patients.
Laparoscopic cholecystectomy was attempted in 18 patients with 6 being converted to open cholecystectomy. Six patients
had biliary stent insertion only and 3 were conservatively managed. Six patients had type II MS, 4 were treated with open
cholecystectomy and Roux-en-Y hepaticojejunostomy, 1 underwent an open subtotal cholecystectomy with fistula closure
and 1 had percutaneous biliary stent insertion only. The median follow-up period was 2 (17) months (n/18). 10 patients
are currently under follow-up. Overall morbidity was 27% (n/8) and mortality was 7% (n/2). Conclusion. Pre-operative
diagnosis of MS can be achieved using MRCP. Laparoscopic cholecystectomy for type I MS is a safe option and type II MS
can be treated with Roux-en-Y hepaticojejunostomy or subtotal cholecystectomy with fistula closure.
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Introduction
Mirizzi’s syndrome (MS) was first described in 1948
as an extrinsic compression of the extrahepatic biliary
system by an impacted stone in the gallbladder neck
or the cystic duct leading to obstructive jaundice [1].
McSherry et al. subsequently classified this syndrome
into two distinct types [2]; type I MS when there is
extrinsic compression of the common hepatic duct by
the gallbladder (Figure 1), and type II MS where the
gallstone erodes from the gallbladder or cystic duct
into the common hepatic duct resulting in a chole-
cystcholedochal fistula [2]. However, this syndrome is
rare and occurs in only 0.71.4% of patients with
gallstone disease [35]. Despite the rarity of this
condition, a pre-operative diagnosis is crucial to
determine the appropriate surgical management.
Since its description there have been changes in
management strategies that include diagnostic mod-
alities, endoscopic therapy, and the emergence of
minimally invasive surgical techniques. This study
presents a retrospective review of the diagnostic work-
up and outcome of MS treated within a single
institution over the past decade.
Methods
Patients diagnosed with MS at the Leeds Teaching
Hospitals NHS Trust during the 11-year period, from
August 1994 to August 2005, were identified using
the hospital’s radiology computer coding system
(Radiology Management System). This search iden-
tifies patients with a definite diagnosis or suspicion of
MS stated in radiology reports, which included
ultrasound scan of the abdomen (USS), abdominal
computer tomography (CT), magnetic resonance
cholangiopancreatography (MRCP) and endoscopic
retrograde cholangiopancreatography (ERCP) re-
ports. MRCP was introduced in 1997. Case notes
of patients were reviewed for demography, clinical
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presentation, diagnostic work-up (liver function tests
and endoscopic/radiological investigations) and clin-
ical outcome (treatment, morbidity and mortality).
USS diagnosis of MS was confirmed with the
presence of dilated intrahepatic ducts and common
hepatic duct up to the point of external compression
by the calculus where the bile duct can be seen to
narrow [6]. Criteria used to diagnose MS with other
radiological modalities (CT, MRCP and ERCP) was
cholangiographic evidence of compression of the bile
duct by a stone impacted in the gallbladder neck or
cystic duct, or the presence of a cholecystcholedochal
fistula in keeping with McSherry et al. [2]. Criteria for
surgical diagnosis of MS in this study was based on
surgical dissection and delineation of structures in the
subhepatic space as described in McSherry et al.
classification [2].
Results
During the study period, 33 patients with MS were
identified of the 3,300 total cholecystectomies per-
formed. The median age at diagnosis was 70 (range:
3590) years and a male to female ratio of 15:18.
Type I MS was diagnosed in 27 patients and six had
type II MS. Acute surgical admissions were the
principal mode of referral in 21 patients, six of
whom were tertiary referrals from district general
hospitals. The remaining 12 patients were in-hospital
referrals from non-surgical specialties.
The most common symptom at presentation was
abdominal pain (n/24), and jaundice (n/15). In
cases of type II MS, five of the six patients presented
with jaundice. The classical triad of symptoms of
cholangitis was present in only seven patients, of
which two patients had type II MS. An abnormality in
one or all liver function tests (alkaline phosphatase,
alanine aminotransferase and bilirubin) was present in
all patients.
USS was used as a primary radiological investiga-
tion in 32 of the 33 patients, and the remaining
patient underwent a CT scan. MS was diagnosed in
four patients based on USS findings alone. One
patient had synchronous common bile duct stones
and three patients with type I MS had an empyema of
the gallbladder managed with percutaneous cholecys-
tostomy. These three patients underwent a cholecys-
tectomy following recovery.
Second line investigations following no definitive
diagnosis on USS (n/28) were contrast enhanced
CT (n/9), MRCP (n/14) and ERCP (n/11)
(Figure 2). CT was indicative of MS in three patients
and demonstrated a cholecystocholedochal fistula in
two patients. Diagnosis was achieved using MRCP in
10 patients and ERCP in 11 patients. ERCP demon-
strated co-incidental common bile duct calculi in four
patients. In the remaining five patients, diagnosis was
made intra-operatively.
18 of 27 patients with type I MS underwent
laparoscopic cholecystectomy, of which six were
converted to open cholecystectomy due to unclear
anatomy (n/5) and intra-operative bleeding (n/1).
Two patients had endoscopic biliary drainage for
cholangitis prior to surgery. Four patients had an
on-table cholangiography. One patient had a laparo-
scopic cholecystoduodenal fistula repair and one with
a synchronous distal common bile duct stricture
underwent a laparoscopic choledochoduodenostomy.
Six patients deemed unfit for surgery due to co-
morbidity underwent endoscopic biliary stent inser-
tion. Two patients declined surgery and one patient
with significant co-morbidities was managed with
antibiotic prophylaxis.
Four of six patients with type II MS were managed
surgically with cholecystectomy and Roux-en-Y he-
paticojejunostomy, two of whom had pre-operative
biliary drainage for cholangitis. Open subtotal chole-
cystectomy with fistula repair using the gallbladder
remnant was performed in one patient. The remain-
ing patient was treated conservatively with percuta-
neous biliary stent insertion due to a cerebrovascular
event following admission (Figure 3).
There were two (7%) in hospital, non-operative
deaths; one patient died following perforation of
the duodenum due to biliary stent migration, and
the other as a result of cholangitis following percuta-
neous biliary stent insertion. Overall morbidity was
27% (n/8) (Table I). Histological examination of the
gallbladders demonstrated cholecystitis and no evi-
dence of malignancy in all cases.
The median follow-up period in 18 patients follow-
ing discharge was 2 (range: 17) months. 10 patients
are still under follow-up. Two patients were lost to
Figure 1. Magnetic resonance cholangiopancreatography demon-
strating type I Mirizzi’s syndrome.
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follow-up and one patient was discharged immediately
back to the nursing home without further follow-up.
Discussion
Despite advances in radiological modalities, diagnosis
of MS is still difficult and is often made intra-
operatively [6]. USS often demonstrates a gallstone
impacted at the neck of the gallbladder or cystic
duct, and an associated dilatation of the biliary tract
[6]. Further imaging is usually required due to
difficulty in differentiating MS from biliary tract or
gallbladder malignancy. In the present series, USS
achieved the diagnosis of type I MS in four patients
which is in keeping with previous reports on the
sensitivity of USS in this disease (4%) [8]. ERCP
may assist in differentiating benign from malignant
strictures with a smooth outline of the stricture and
delineation of a cholecystcholedochal fistula being
indicators of type II MS [9]. ERCP also has a
therapeutic role and improved outcomes have been
reported following pre-operative biliary drainage for
cholangitis or jaundice [5,10,11]. Four patients in
the present study underwent biliary drainage endo-
scopically for cholangitis prior to definitive surgical
treatment. The introduction of MRCP has altered
our management practice as it provides equivalent
information to ERCP, without the inherent risk of
complications [12,13]. The diagnostic predictive
value of ERCP was similar to MRCP in this study.
Studies from other centers have reported similar
findings, making MRCP the preferred choice of
investigation [12,13]. There is no study to date
assessing CT scan as a diagnostic modality for MS,
although we found that it identified a chole-cystcho-
ledochal fistula in two of the three patients with type
II MS.
USS is usually the first-line investigation for
patients with abdominal pain and jaundice. Further
imaging in cases with equivocal findings depends on
the patient’s co-morbidities and synchronous biliary
tract pathology. We suggest MRCP as the next
investigation and ERCP should be reserved for
patients where therapeutic intervention is required.
CT examination may assist in determining the pre-
sence of a cholecyst-choledochal fistula and in cases of
suspected malignancy. However, its exact role is
uncertain.
Study sample with
Mirizzi’s syndrome (n = 33)
                   USS (n = 32)                             CT (n = 1)
   Diagnostic of                             No definitive                         Diagnostic of
Mirizzi’s syndrome                                    diagnosis                       Mirizzi’s syndrome
        (n = 4)                                                 (n = 28)                                  (n = 1)
            CT                                MRCP                            ERCP                           Surgery
     diagnostic of                   diagnostic of                 diagnostic of                 intra-operative
Mirizzi’s syndrome         Mirizzi’s syndrome       Mirizzi’s syndrome              diagnosis
         (n = 2)                         (n = 10)                          (n = 11)                   (n = 5)
USS – Ultrasound scan of the abdomen
MRCP – Magnetic Resonance Cholangiopancreatography
ERCP – Endoscopic Retrograde Cholangiopancreatography
CT – Computer tomography
Figure 2. Imaging performed on patients in our study.
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The surgical management of MS presents a de-
manding technical challenge to clinicians. Some
authors consider this syndrome a contraindication
for laparoscopic intervention due to the anatomical
variability present in this syndrome [1416] whereas
others have reported successful laparoscopic surgery
for type I MS albeit technically challenging [14,
1719]. Interventions to enhance laparoscopic suc-
cess include intra-operative cholangiography [4] or
intra-operative ultrasound to delineate biliary tract
anatomy prior to dissection [18]. Previous studies
have reported technical difficulties during the dissec-
tion phase around Calot’s triangle, and removal of the
entire gallbladder increased the risk of inadvertently
damaging the common bile duct [19,20]. Karademir
et al. suggested laparoscopic partial cholecystectomy
to be a safe and definitive surgical treatment for type I
MS [21]. It is thought that bile duct narrowing caused
by external compression of the offending gallstone
with its associated inflammatory tissue generally
resolves following decompression with partial chole-
cystectomy [20]. Nevertheless, failure of the laparo-
scopic approach and high conversion rates (17% [22],
100% [23]) have been reported and these are often
due to extensive dense adhesions, uncontrollable
haemorrhage and failure of completely retrieving all
gallstones impacted in the cholecystcholedochal fis-
tula [22,23]. In this series, the majority of patients
with type I MS were treated successfully by laparo-
scopic cholecystectomy. In this series, the majority of
Study sample with Mirizzi’s syndrome (n = 33)
     Type I Mirizzi’s syndrome (n = 27)   Type II Mirizzi’s syndrome (n = 6)
   Attempted            ERCP &                  Conservative           Surgery PTC & biliary
  Laparoscopic       biliary stenting            management            (n = 5)          stenting (n = 1)
Cholecystectomy      (n = 6)                         (n = 3)
     (n = 18)
                                                                    Cholecystectomy                    Subtotal
 Converted               Laparoscopic       & Roux-en-Y                  cholecystectomy &
  to open                       Surgery                  hepaticojejunostomy            suture closure of
cholecystectomy    (n = 12)                        (n = 4)                        gallbladder remnant
    (n = 6)                                                                                                 (n = 1)
                   Complete                              Subtotal
              cholecystectomy                 cholecystectomy
                    (n = 11)                                  (n = 1)
ERCP – Endoscopic Retrograde Cholangiopancreatography
PTC – Percutaneous Transhepatic Cholangiography
Figure 3. Management of patients with Mirizzi’s syndrome based on the McSherry et al. classification in this study.
Table I. Morbidity data on surgical, endoscopic and radiological treatment of Mirizzi’s syndrome in this study.
Mirizzi’s syndrome type No. of cases (n/30) Management of patients Morbidity (n/8, 27%)
Type I 24 Surgery (n/18) Subphrenic collection (n/2) Cholangitis (n/1)
Endoscopic stenting (n/6) Pancreatitis (n/1) Duodenal perforation secondary
to biliary stent migration (n/1)
Type II 6 Surgery (n/5) Biliary leak (n/2)
Percutaneous stenting (n/1) Multi-organ failure (n/1)
ERCP  Endoscopic Retrograde Cholangiopancreatography
PTC  Percutaneous Transhepatic Cholangiography
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patients with type I MS were treated successfully by
laparoscopic cholecystectomy, suggesting that laparo-
scopic surgery is a safe surgical option when applied in
the appropriate settings with a low threshold for
conversion to the open technique. It is crucial to limit
dissection away from the area of inflammation adja-
cent to the common bile duct to avoid possible injury.
The surgical management of type II MS is largely
dependent on the size of the cholecystocholedochal
fistula and the experience of the surgeon. A recent
study reported the successful laparoscopic treatment
of type II MS following pre-operative endoscopic
biliary stenting which enabled intra-operative identi-
fication of the common bile duct [14]. Other studies
favour open techniques, [4,5,10,11,20,21,24] which
include partial chole-cystectomy with primary clo-
sure, Roux-en-Y hepaticojejunostomy, cholecysto-
duodenostomy and choledochoplasty with gallbladder
flap [4,5,10,11,20,21,24]. Partial chole-cystectomy
with primary closure using the gallbladder remnant
and T-tube placement through the fistula opening is
considered an appropriate surgical option by some
authors [21,25]. Baer et al. suggest the use of bilio-
enteric bypass of the cholecystocholedochal fistula
rather than direct repair of the fistula after observing
poor results in one instance [20]. Although the direct
closure configuration is thought to be prone to bile
leakage and stricture formation, [20] Sharma et al.
observed good long term results in patients who
underwent primary closure of the cholecystocholedo-
chal fistula using a cuff of the gallbladder [11]. T-tube
insertion into the common bile duct rather than the
fistula opening following this procedure is thought to
reduce the risk of stenosis by decompressing the
common bile duct [11,26]. In cases with a wider
defect in the bile duct, Roux-en-Y hepaticojejunost-
omy is recommended to avoid complications such as
biliary leakage, cholangitis and stricture formation [4]
[11,20,21]. Although the majority of the patients with
type II MS in this study underwent a cholecystectomy
and Roux-en-Y hepatico-jejunostomy, subtotal chole-
cystectomy with fistula repair using gallbladder rem-
nant is also an option.
There are a number of published reports on
percutaneous [27,28] and endoscopic [8,29] biliary
drainage as a treatment option in MS cases. England
et al. found endoscopic therapy an effective temporiz-
ing measure prior to definitive surgical intervention in
almost half their patients [8] and recommended an
endoscopic approach for unsuitable surgical candi-
dates with type II MS [8]. Our study reported similar
findings with endoscopic biliary stenting being used as
a definitive treatment option in patients with signifi-
cant co-morbidities.
None of the patients in this study had unsuspected
gallbladder carcinoma. The incidence of gallbladder
cancer in patients with MS is significantly higher
than the incidence in longstanding gallstone disease
which have been noted to be 27% and 2% respec-
tively [30].
Conclusion
Pre-operative diagnosis of MS can be achieved using
MRCP. In cases of type I MS, laparoscopic cholecys-
tectomy is a safe option albeit with a low threshold for
conversion to an open procedure. The surgical
management of type II MS largely depends on the
size of the fistula and a cholecystectomy and Roux-en-
Y hepaticojejunostomy or subtotal cholecystectomy
with closure of fistula using gallbladder remnant are
both treatment options. Endoscopic biliary stent
insertion is suitable for patients requiring pre-opera-
tive biliary drainage or those with significant co-
morbidity.
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